Skip to content
HowShorted

SOLENO THERAPEUTICS INC short interest in 2025

In 2025, SOLENO THERAPEUTICS INC's disclosed short interest ran from 10.97% of shares outstanding on 15 Jan 2025 to 20.35% on 31 Dec 2025, a change of +9.38 percentage points. The year's high was 20.35% on 31 Dec 2025 and its low 7.91% on 30 May 2025, averaging 12.72% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.27 days on 14 Feb 2025. Full history: SOLENO THERAPEUTICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for SOLENO THERAPEUTICS INC in 2025

2025 in figures

Start of year
10.97% (15 Jan 2025)
End of year
20.35% (31 Dec 2025)
Change
+9.38 pp
High
20.35% (31 Dec 2025)
Low
7.91% (30 May 2025)
Average
12.72%
Highest days to cover
11.27 (14 Feb 2025)
SEC filings marked
10

Every report in 2025

SOLENO THERAPEUTICS INC short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202510.97%9.51
31 Jan 202510.09%11.25
14 Feb 202510.53%11.27
28 Feb 202511.15%11.04results (8-K), 10-K filed
14 Mar 202511.57%7.18
31 Mar 202510.81%1.59results (8-K)
15 Apr 202511.62%2.92
30 Apr 20259.66%4.38
15 May 20258.23%4.9510-Q filed, results (8-K)
30 May 20257.91%6.43
13 Jun 20258.06%6.01
30 Jun 202510.62%3.73
15 Jul 202511.64%3.61results (8-K)
31 Jul 202511.99%5.50
15 Aug 202511.87%3.3210-Q filed, results (8-K)
29 Aug 202514.27%6.13
15 Sep 202513.64%3.30
30 Sep 202516.23%3.33
15 Oct 202515.87%5.80
31 Oct 202515.80%6.51
14 Nov 202518.12%2.9610-Q filed, results (8-K)
28 Nov 202516.93%5.50
15 Dec 202517.23%6.21
31 Dec 202520.35%9.58

See also: SOLENO THERAPEUTICS INC's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.